OSE Immunotherapeutics S.A.
OSE.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €70 | €2 | €18 | €26 |
| % Growth | 3,037.7% | -87.8% | -30.4% | – |
| Cost of Goods Sold | €0 | €0 | €0 | €0 |
| Gross Profit | €70 | €2 | €18 | €26 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | €33 | €17 | €27 | €31 |
| G&A Expenses | €6 | €6 | €7 | €9 |
| SG&A Expenses | €9 | €8 | €10 | €12 |
| Sales & Mktg Exp. | €3 | €2 | €3 | €4 |
| Other Operating Expenses | €0 | €0 | €0 | €0 |
| Operating Expenses | €42 | €25 | €37 | €43 |
| Operating Income | €44 | -€23 | -€18 | -€17 |
| % Margin | 62.6% | -1,032.2% | -101% | -63.2% |
| Other Income/Exp. Net | -€4 | -€0 | €0 | -€1 |
| Pre-Tax Income | €40 | -€23 | -€23 | -€22 |
| Tax Expense | €2 | -€0 | -€6 | -€5 |
| Net Income | €37 | -€23 | -€18 | -€17 |
| % Margin | 53.6% | -1,032.9% | -97% | -64.1% |
| EPS | 1.72 | -1.18 | -0.96 | -0.93 |
| % Growth | 245.8% | -22.9% | -3.2% | – |
| EPS Diluted | 1.72 | -1.18 | -0.96 | -0.93 |
| Weighted Avg Shares Out | 22 | 20 | 18 | 18 |
| Weighted Avg Shares Out Dil | 22 | 20 | 18 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | €1 | €0 | €0 | €0 |
| Interest Expense | €3 | €2 | €1 | €1 |
| Depreciation & Amortization | €3 | €4 | €4 | €3 |
| EBITDA | €41 | -€18 | -€13 | -€14 |
| % Margin | 59% | -785.9% | -71.6% | -52.2% |